Posters
Patient satisfaction and visual function after bilateral pseudophakia: multifocal IOL for one eye and monofocal IOL for second eye
Poster Details
First Author: A. Ivashina RUSSIAN FEDERATION
Co Author(s): N. Korshunova M. Gulyayev V. Neyasov V. Malyshev
Abstract Details
Purpose:
To evaluate visual function and patient satisfaction after bilateral implantation: multifocal iol for one eye and monofocal iol for second eye.
Setting:
“OKOMED” Ophthalmic clinic, Moscow, Russia
Methods:
10 eyes of 5 patients aged 27 to 77 years (mean age 56.60±0.52) underwent Phacoemulsification through 2.2 mm corneal incision with IOL implantation LentisMplus LS-313MF30 (Oculentis GmbH) for one eye and MicroAY123 (PhysIOL, Belgium) for second eye. For IOL calculation we used IOL Master (Carl Zeiss Meditec), the optical power of IOLs was+9.0D to +21.5D. Preoperative refraction ranged from -3.0D to -14.5D (mean -7.75±035D).The reasons of monofocal IOL implantation were retinal pathologies, unclear vision, amblyopia or finance difficulties. Laser retinal coagulation in 4 high myopic patients was performed before surgery. The follow-up period – 4 months to 1.5 years.
Results:
All patients had Post-op binocular vision. Stereo visual acuity was from 140 to 40sec. Post-op SE was from -0.25D to -3.0D (-1.22 ±0.1D). UCDVA was from 0.15 to 1.0 (0.76±0.04): in monofocal eyes – from 0.15 to 1.1, in multifocal eyes 0.7-1.0. Post-op BCDVA was from 0.7 to 1.2 (1.01±0.01): monofocal eyes 0.7-1.2, multifocal- 1.0-1.2. Post-op UCNVA was from 0.6 to 1.0 (0.76±0.07). 4 patients didn`t need spectacles for near. They had no problems for sport, no difficulty in reading a newspaper, driving and watching television, computer. 2 patients had a little difficulty in nighttime driving. 4 of 5 patients were very happy. Only 1 patient – stomatology doctor had a little difficulty in binocular vision for near.
Conclusions:
Bilateral pseudophakia with multifocal IOL in one eye and monofocal IOL in second eye is efficient to receive high binocular vision acuity for far and near.
Financial Disclosure:
NONE